Stock Analysis on Net
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Return on Assets (ROA)
since 2005

Microsoft Excel

Paying user area

Try for free

Johnson & Johnson pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Johnson & Johnson, ROA, long-term trends, calculation

Microsoft Excel
ROA = 100 × Net earnings1 ÷ Total assets1
Dec 29, 2024 = 100 × ÷
Dec 31, 2023 = 100 × ÷
Dec 31, 2022 = 100 × ÷
Dec 31, 2021 = 100 × ÷
Dec 31, 2020 = 100 × ÷
Dec 29, 2019 = 100 × ÷
Dec 30, 2018 = 100 × ÷
Dec 31, 2017 = 100 × ÷
Dec 31, 2016 = 100 × ÷
Dec 31, 2015 = 100 × ÷
Dec 28, 2014 = 100 × ÷
Dec 29, 2013 = 100 × ÷
Dec 30, 2012 = 100 × ÷
Dec 31, 2011 = 100 × ÷
Dec 31, 2010 = 100 × ÷
Dec 31, 2009 = 100 × ÷
Dec 28, 2008 = 100 × ÷
Dec 30, 2007 = 100 × ÷
Dec 31, 2006 = 100 × ÷
Dec 31, 2005 = 100 × ÷

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions

The analysis of the financial data reveals several notable trends and fluctuations in the company's performance over the years under review.

Net Earnings
Net earnings exhibit variability throughout the periods. Initially, there is a general upward trend from 2005 (US$10,411 million) to 2010 (US$13,334 million), followed by a decline in 2011 (US$9,672 million). Subsequently, earnings increase again until 2014, reaching a peak above US$16,000 million. A significant decline occurs in 2017 to US$1,300 million, which is an outlier compared to the other years. After this dip, earnings recover to approximately pre-dip levels, peaking in 2023 at US$35,153 million, before dropping sharply again in 2024 (US$14,066 million).
Total Assets
Total assets show a consistent upward trajectory from 2005 through 2021, increasing from US$58,025 million to US$182,018 million. There is a slight increase continuing in 2022 (US$187,378 million), but a noticeable decrease occurs in 2023 to US$167,558 million, before recovering somewhat in 2024 (US$180,104 million). Overall, asset growth appears strong and steady with minor fluctuations toward the end of the period.
Return on Assets (ROA)
ROA percentages fluctuate significantly over the years. It starts high in 2005 at 17.94% and generally trends downward until 2011, where it reaches a low of 8.51%. Some recovery is seen in subsequent years, but the ROA widens its variability, with a remarkably low value of 0.83% in 2017 consistent with the sharp drop in net earnings. Following this, ROA resumes a moderate upward trend, peaking at 20.98% in 2023, which coincides with the peak in net earnings. In 2024, ROA decreases again to 7.81%, aligning with the decrease in net earnings and assets in that year.

In summary, the company’s financial performance is characterized by generally increasing assets and an overall upward trajectory in net earnings and profitability, despite several pronounced fluctuations. Significant volatility is evident around 2017 and 2023, where both net earnings and ROA display marked deviations from surrounding years. These anomalies suggest extraordinary events or operational challenges impacting profitability and asset utilization during those periods. The most recent data for 2024 indicate a reduction in earnings, assets, and ROA, signaling a potential decrease in financial performance that merits further investigation.

Comparison to Competitors

Johnson & Johnson, ROA, long-term trends, comparison to competitors

Microsoft Excel
Johnson & Johnson AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 29, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 29, 2019
Dec 30, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 28, 2014
Dec 29, 2013
Dec 30, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 28, 2008
Dec 30, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Johnson & Johnson, ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
Johnson & Johnson Pharmaceuticals, Biotechnology & Life Sciences
Dec 29, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 29, 2019
Dec 30, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 28, 2014
Dec 29, 2013
Dec 30, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 28, 2008
Dec 30, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Industry (Health Care)

Johnson & Johnson, ROA, long-term trends, comparison to industry (health care)

Microsoft Excel
Johnson & Johnson Health Care
Dec 29, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 29, 2019
Dec 30, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 28, 2014
Dec 29, 2013
Dec 30, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 28, 2008
Dec 30, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).